When these fundamentals are in place, lean muscle can be effectively maintained while using these therapies
Albiglutide Albiglutide achieves extended systemic activity through genetic fusion with human serum albumin (HSA), a strategy distinct from the fatty acid-based albumin binding used in agents like liraglutide and semaglutide
(See Figure 2 for a timeline of key activities associated with the GLP-1 coverage demonstrations.) Medicare coverage of GLP-1s for obesity begins in July 2026 through the Medicare GLP-1 Bridge and will be extended through the end of 2027 CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 (originally December 31, 2026) through the Medicare GLP-1 Bridge, which is a short-term demonstration established using Section 402 demonstration authority
21, 2025 Indiana HB1138 and Indiana HB1202 and Indiana HB1552 BillTrack50
Schirra, J
Research shows that after 20 months, a weight loss peptide called Tirzepatide resulted in an average of 25.3% reduction in weight for nearly 700 participants
